Citations (104)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (16)
H.L. Katzeff, D. Williams-Herman, L. Xu, G.T. Golm, H. Wang, Q. Dong, J.R. Johnson, E.A. O’Neill, K.D. Kaufman, S.S. Engel & B.J. Goldstein. (2015) Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes. Current Medical Research and Opinion 31:6, pages 1071-1077.
Read now
Read now
Ronnie Aronson. (2015) Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin. Current Medical Research and Opinion 31:5, pages 901-911.
Read now
Read now
Qingwei Zhao, Dongsheng Hong, Dongsheng Zheng, Yao Xiao & Baohua Wu. (2014) Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials. Drug Design, Development and Therapy 8, pages 2283-2294.
Read now
Read now
Theodosios D Filippatos, Vasilios G Athyros & Moses S Elisaf. (2014) The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors. Expert Opinion on Drug Metabolism & Toxicology 10:6, pages 787-812.
Read now
Read now
Helmut Steinberg, Matt S Anderson, Thomas Musliner, Mary E Hanson & Samuel S Engel. (2013) Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin. Vascular Health and Risk Management 9, pages 273-282.
Read now
Read now
Qiang Du, Bo Wu, Yan-Jun Wang, Sheng Yang, Yue-Yang Zhao & Yuan-yuan Liang. (2013) Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis. Current Medical Research and Opinion 29:11, pages 1487-1494.
Read now
Read now
Marc Rendell, Andjela Drincic & Radha Andukuri. (2012)
Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 13:4, pages 553-563.
Read now
Read now
Giuseppe Derosa & Pamela Maffioli. (2011) Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 4, pages 263-271.
Read now
Read now
Sheila A Doggrell. (2011) Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials. Expert Opinion on Pharmacotherapy 12:13, pages 2055-2067.
Read now
Read now
Baptist Gallwitz. (2011) Sitagliptin and metformin combination therapy for the treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 6:4, pages 543-556.
Read now
Read now
Karen Barnard, Mary Elizabeth Cox & Jennifer B Green. (2010) Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 3, pages 363-372.
Read now
Read now
André J Scheen. (2010) Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. Expert Opinion on Drug Metabolism & Toxicology 6:10, pages 1265-1276.
Read now
Read now
Thomas Blevins. (2010) Therapeutic Options that Provide Glycemic Control and Weight Loss for Patients with Type 2 Diabetes. Postgraduate Medicine 122:1, pages 172-183.
Read now
Read now
James R. LaSalle. (2010) Reaching HbA1c Goals with Saxagliptin in Combination with Other Oral Antidiabetic Drugs. Postgraduate Medicine 122:1, pages 144-152.
Read now
Read now
Radha Andukuri, Andjela Drincic & Marc Rendell. (2009) Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes, Metabolic Syndrome and Obesity 2, pages 117-126.
Read now
Read now
Anna I. Palalau, Abd A. Tahrani, Milan K. Piya & Anthony H. Barnett. (2009) DPP-4 Inhibitors in Clinical Practice. Postgraduate Medicine 121:6, pages 70-100.
Read now
Read now
Articles from other publishers (88)
E. V. Biryukova & D. V. Kileynikov. (2023) Metformin and sitagliptin fixed combination as the optimal choice in solving current problems in the type 2 diabetes mellitus treatment. Meditsinskiy sovet = Medical Council 17:9, pages 23-30.
Crossref
Crossref
Xiaoping Chen, Hongwei Jiang, Hongmei Li, Hongyu Kuang, Li Chen, Jianhua Ma, Qiu Zhang, Tianrong Pan & Wenying Yang. (2022)
Saxagliptin combined with additional oral antihyperglycaemic agents in drug‐naive diabetic patients with high glycosylated haemoglobin: A 24‐week, multicentre, randomized, open‐label, active parallel‐controlled group clinical trial in China (
SUCCESS
)
. Diabetes, Obesity and Metabolism 25:1, pages 272-281.
Crossref
Crossref
Anshul Kaushik, Rimjhim Sangtani, Hamendra Singh Parmar & Kiran Bala. (2023) Algal metabolites: Paving the way towards new generation antidiabetic therapeutics. Algal Research 69, pages 102904.
Crossref
Crossref
Xiayun Ni, Lei Zhang, Xiaojun Feng & Liqin Tang. (2022) New Hypoglycemic Drugs: Combination Drugs and Targets Discovery. Frontiers in Pharmacology 13.
Crossref
Crossref
Muhammad Yazid Jalaludin, Asma Deeb, Philip Zeitler, Raymundo Garcia, Ron S. Newfield, Yulia Samoilova, Carmen A. Rosario, Naim Shehadeh, Chandan K. Saha, Yilong Zhang, Martina Zilli, Lynn W. Scherer, Raymond L. H. Lam, Gregory T. Golm, Samuel S. Engel, Keith D. Kaufman & R. Ravi Shankar. (2021) Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin. Pediatric Diabetes 23:2, pages 183-193.
Crossref
Crossref
R. Ravi Shankar, Philip Zeitler, Asma Deeb, Muhammad Yazid Jalaludin, Raymundo Garcia, Ron S. Newfield, Yulia Samoilova, Carmen A. Rosario, Naim Shehadeh, Chandan K. Saha, Yilong Zhang, Martina Zilli, Lynn W. Scherer, Raymond L. H. Lam, Gregory T. Golm, Samuel S. Engel & Keith D. Kaufman. (2021) A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes. Pediatric Diabetes 23:2, pages 173-182.
Crossref
Crossref
Ping Shi, Xin Liu, Ting Li, Fei-fei Sun, Yan-ping Liu, Shu-qin Liu, Xiao-meng Gao, Ya-ping Ma, Yao Fu & Yu Cao. (2021) Pharmacokinetics and Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese Subjects: A Randomized, Open-Label, Crossover Study. Drugs in R&D 22:1, pages 15-23.
Crossref
Crossref
Filip Gnesin, Anne Cathrine Baun Thuesen, Lise Katrine Aronsen Kähler, Sten Madsbad & Bianca Hemmingsen. (2020) Metformin monotherapy for adults with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2020:6.
Crossref
Crossref
Derya Bal Altuntaş. (2020) Development of All‐solid‐state Antidiabetic Drug Metformin‐selective Microsensor and its Electrochemical Applications. Electroanalysis 32:6, pages 1280-1287.
Crossref
Crossref
Chengzhi Zhang & Guiying Yan. (2019) Synergistic drug combinations prediction by integrating pharmacological data. Synthetic and Systems Biotechnology 4:1, pages 67-72.
Crossref
Crossref
Iain P. Fraser, Naomi D. Neufeld, Larry A. Fox, Mark S. Kipnes, Tracie L. Miller, Philip S. Zeitler, Henry Rodriguez, Jocelyn H. Gilmartin, Susan J. Lee, Jaclyn K. Patterson, Xiujiang S. Li, Lata Maganti, Wen-Lin Luo, Daniel A. Tatosian & S. Aubrey Stoch. (2019) A randomized clinical trial to evaluate the single-dose pharmacokinetics, pharmacodynamics, and safety of sitagliptin in pediatric patients with type 2 diabetes. Pediatric Diabetes 20:1, pages 48-56.
Crossref
Crossref
Ganesh V. Sangle, Mohan Patil, Nitin J. Deshmukh, Sushant A. Shengule, Shantibhushan Kamble, Kiran Kumar Vuppalavanchu, Sushil Kale, Mirza Layeeq Ahmed Baig, Geetchandra Singh, Javed Shaikh, Jitendra Tripathi & P. Aravindababu. (2018) Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin in healthy Indian males. European Journal of Clinical Pharmacology 74:5, pages 561-569.
Crossref
Crossref
Xuejun V. Peng, John F. Marcinak, Marsha G. Raanan & Charlie Cao. (2017) Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial. Diabetes, Obesity and Metabolism 19:8, pages 1127-1134.
Crossref
Crossref
Xiafei Lyu, Xiaolin Zhu, Bin Zhao, Liang Du, Dawei Chen, Chun Wang, Guanjian Liu & Xingwu Ran. (2017) Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials. Scientific Reports 7:1.
Crossref
Crossref
Cristina Bianchi, Giuseppe Daniele, Angela Dardano, Roberto Miccoli & Stefano Del Prato. (2017) Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. Drugs 77:3, pages 247-264.
Crossref
Crossref
Soo Lim, Kyung Ah Han, JaeMyung Yu, Parinya Chamnan, Eun Sook Kim, Kun-Ho Yoon, Sam Kwon, Min Kyong Moon, Kwan Woo Lee, Dong-Jun Kim, Mikyung Kim, Manaj Wongtanate, Eun Young Kim, Sung-Ho Kim & Moon-Kyu Lee. (2017) Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study). Diabetes, Obesity and Metabolism 19:1, pages 87-97.
Crossref
Crossref
Ariana Mooradian, Joe M. Chehade & Arshag D. Mooradian. (2016) Advantages and Pitfalls of Antihyperglycemic Combination Pills as First-Line Therapy in the Management of Type 2 Diabetes. American Journal of Therapeutics 23:6, pages e1857-e1866.
Crossref
Crossref
Robert G. Moses, Elizabeth Round, Yue Shentu, Gregory T. Golm, Edward A. O'neill, Ira Gantz, Samuel S. Engel, Keith D. Kaufman & Barry J. Goldstein. (2016) A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. Journal of Diabetes 8:5, pages 701-711.
Crossref
Crossref
Steven Milligan. (2016) Combination therapy for the improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: Rationale and evidence for early initiation. Journal of Diabetes and its Complications 30:6, pages 1177-1185.
Crossref
Crossref
Je-Yon Kim, Seungwon Yang, Jangik I. Lee & Min Jung Chang. (2016) Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis. PLOS ONE 11:4, pages e0153502.
Crossref
Crossref
D. Polidori, G. Capuano & R. Qiu. (2016) Apparent subadditivity of the efficacy of initial combination treatments for type 2 diabetes is largely explained by the impact of baseline HbA1c on efficacy. Diabetes, Obesity and Metabolism 18:4, pages 348-354.
Crossref
Crossref
Julio Rosenstock, Leonard Chuck, Manuel González-Ortiz, Kate Merton, Jagriti Craig, George Capuano & Rong Qiu. (2016) Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes. Diabetes Care 39:3, pages 353-362.
Crossref
Crossref
Carolyn F Deacon. 2016. Handbook of Incretin-based Therapies in Type 2 Diabetes. Handbook of Incretin-based Therapies in Type 2 Diabetes
45
60
.
Abdulrahman S. Alanazi. (2015) Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitors. Saudi Pharmaceutical Journal 23:6, pages 603-613.
Crossref
Crossref
Isma Haq, Adnan Mujahid, Adeel Afzal, Naseer Iqbal, Sadia Zafar Bajwa, Tajamal Hussain, Khurram Shehzad & Hadia Ashraf. (2015) Developing imprinted polymer nanoparticles for the selective separation of antidiabetic drugs. Journal of Separation Science 38:19, pages 3469-3476.
Crossref
Crossref
R. R. Shankar, L. Xu, G. T. Golm, E. A. O'Neill, B. J. Goldstein, K. D. Kaufman & S. S. Engel. (2015) A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. International Journal of Clinical Practice 69:6, pages 626-631.
Crossref
Crossref
M. E. Rotz, V. S. Ganetsky, S. Sen & T. F. Thomas. (2015) Implications of incretin-based therapies on cardiovascular disease. International Journal of Clinical Practice 69:5, pages 531-549.
Crossref
Crossref
LIQIONG HOU, TIEYUN ZHAO, YUNHUI LIU & YIYI ZHANG. (2015) Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis. Experimental and Therapeutic Medicine 9:4, pages 1528-1536.
Crossref
Crossref
Linong Ji, Bernard Zinman, Sanjay Patel, Jinfeng Ji, Zelie Bailes, Sandra Thiemann & Thomas Seck. (2015) Efficacy and Safety of Linagliptin Co-Administered with Low-Dose Metformin Once Daily Versus High-Dose Metformin Twice Daily in Treatment-Naïve Patients with Type 2 Diabetes: a Double-Blind Randomized Trial. Advances in Therapy 32:3, pages 201-215.
Crossref
Crossref
Yan-rong Ma, Jing Huang, Yun-yun Shao, Kang Ma, Guo-qiang Zhang, Yan Zhou, Rao Zhi, Hong-yan Qin & Xin-an Wu. (2015) Inhibitory effect of atenolol on urinary excretion of metformin via down-regulating multidrug and toxin extrusion protein 1 (rMate1) expression in the kidney of rats. European Journal of Pharmaceutical Sciences 68, pages 18-26.
Crossref
Crossref
Ricardo Godinho, Cristina Mega, Edite Teixeira-de-Lemos, Eugénia Carvalho, Frederico Teixeira, Rosa Fernandes & Flávio Reis. (2015) The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?. Journal of Diabetes Research 2015, pages 1-28.
Crossref
Crossref
Guillermo Umpierrez, Santiago Tofé Povedano, Federico Pérez Manghi, Linda Shurzinske & Valeria Pechtner. (2014) Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3). Diabetes Care 37:8, pages 2168-2176.
Crossref
Crossref
R. E. Pratley, P. Fleck & C. Wilson. (2014) Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study. Diabetes, Obesity and Metabolism 16:7, pages 613-621.
Crossref
Crossref
Paul Craddy, Hannah-Jayne Palin & K. Ian Johnson. (2014) Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. Diabetes Therapy 5:1, pages 1-41.
Crossref
Crossref
O. J. Phung, D. M. Sobieraj, S. S. Engel & S. N. Rajpathak. (2014) Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes, Obesity and Metabolism 16:5, pages 410-417.
Crossref
Crossref
Elizabeth M. Round, Samuel S. Engel, Gregory T. Golm, Michael J. Davies, Keith D. Kaufman & Barry J. Goldstein. (2014) Safety of Sitagliptin in Elderly Patients with Type 2 Diabetes: A Pooled Analysis of 25 Clinical Studies. Drugs & Aging 31:3, pages 203-214.
Crossref
Crossref
Mohd. Riaz, Imran Imran, Rinu Manuel & Nidhisha K Joseph. (2014) AN OBSERVATIONAL STUDY COMPARING SITAGLIPTIN TO METFORMIN AS A INITIAL MONOTHERAPY IN TYPE 2 DIABETES MELLITUS PATIENTS. Journal of Evolution of Medical and Dental Sciences 3:7, pages 1698-1703.
Crossref
Crossref
Irfan Vardarli, Elisabeth Arndt, Carolyn F. Deacon, Jens J. Holst & Michael A. Nauck. (2014) Effects of Sitagliptin and Metformin Treatment on Incretin Hormone and Insulin Secretory Responses to Oral and “Isoglycemic” Intravenous Glucose. Diabetes 63:2, pages 663-674.
Crossref
Crossref
W. Gao, J. Dong, J. Liu, Y. Li, F. Liu, L. Yang, X. Zhou & L. Liao. (2014) Efficacy and safety of initial combination of DPP-IV inhibitors and metformin versus metformin monotherapy in type 2 diabetes: a systematic review of randomized controlled trials. Diabetes, Obesity and Metabolism 16:2, pages 179-185.
Crossref
Crossref
Y. Liu & T. Hong. (2014) Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. Diabetes, Obesity and Metabolism 16:2, pages 111-117.
Crossref
Crossref
Greg L. Plosker. (2014) Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 74:2, pages 223-242.
Crossref
Crossref
Fatemeh Hayati, Amjed Hazim, Teguh Haryo Sasongko, Gan Siew Hua, Wan Mohd Izani Wan Mohamed, Juhaida Daud, Nik Soriani Yaacob & Wan Mohamad Wan Bebakar. (2014) Efficacy and safety of sitagliptin as a third therapeutic agent in the treatment of type 2 diabetes mellitus. Journal of Diabetes Research and Clinical Metabolism 3:1, pages 10.
Crossref
Crossref
Sri Harsha Tella, Halis Kaan Akturk & Marc Rendell. (2014) Linagliptin for the treatment of Type 2 diabetes. Diabetes Management 4:1, pages 85-101.
Crossref
Crossref
Shu Meguro, Toshihide Kawai, Tomohiro Matsuhashi, Motoaki Sano, Keiichi Fukuda, Hiroshi Itoh & Yoshihiko Suzuki. (2014) Basal-Supported Oral Therapy with Sitagliptin Counteracts Rebound Hyperglycemia Caused by GLP-1 Tachyphylaxis. International Journal of Endocrinology 2014, pages 1-5.
Crossref
Crossref
D. Wu, L. Li & C. Liu. (2014) Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes, Obesity and Metabolism 16:1, pages 30-37.
Crossref
Crossref
Jin Lu, Jiajie Zang & Huihua Li. (2013) Impact of Three Oral Antidiabetic Drugs on Markers of ?-Cell Function in Patients with Type 2 Diabetes: A Meta-Analysis. PLoS ONE 8:10, pages e76713.
Crossref
Crossref
Samuel S. Engel, Thomas L. Seck, Gregory T. Golm, Alan G. Meehan, Keith D. Kaufman & Barry J. Goldstein. (2013) Assessment of AACE/ACE Recommendations for Initial Dual Antihyperglycemic Therapy Using the Fixed-Dose Combination of Sitagliptin and Metformin Versus Metformin. Endocrine Practice 19:5, pages 751-757.
Crossref
Crossref
R. E. van Genugten, D. L. Möller‐Goede, D. H. van Raalte & M. Diamant. (2013) Extra‐pancreatic effects of incretin‐based therapies: potential benefit for cardiovascular‐risk management in type 2 diabetes. Diabetes, Obesity and Metabolism 15:7, pages 593-606.
Crossref
Crossref
Samuel S. Engel, Elizabeth Round, Gregory T. Golm, Keith D. Kaufman & Barry J. Goldstein. (2013) Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies. Diabetes Therapy 4:1, pages 119-145.
Crossref
Crossref
Brian Zambrowicz, Zhi-Ming Ding, Ike Ogbaa, Kenny Frazier, Phillip Banks, Anne Turnage, Joel Freiman, Melinda Smith, Dennis Ruff, Arthur Sands & David Powell. (2013) Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes. Clinical Therapeutics 35:3, pages 273-285.e7.
Crossref
Crossref
Chitrabhanu BallavStephen C.L. Gough. (2013) Safety and Efficacy of Sitagliptin-Metformin in Fixed Combination for the Treatment of Type 2 Diabetes Mellitus. Clinical Medicine Insights: Endocrinology and Diabetes 6, pages CMED.S7314.
Crossref
Crossref
Samuel S Engel, Gregory T Golm, Deborah Shapiro, Michael J Davies, Keith D Kaufman & Barry J Goldstein. (2013) Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovascular Diabetology 12:1, pages 3.
Crossref
Crossref
Takafumi Senmaru, Michiaki Fukui, Kanae Kobayashi, Hiroya Iwase, Shinobu Inada, Hiroshi Okada, Mai Asano, Masahiro Yamazaki, Goji Hasegawa, Naoto Nakamura, Masahiro Iwasaki, Daisuke Yabe, Takeshi Kurose & Yutaka Seino. (2012) Dipeptidyl‐peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations. Journal of Diabetes Investigation 3:6, pages 498-502.
Crossref
Crossref
Wenying YANG, Yanfen GUAN, Yue SHENTU, Zhi LI, Amy O. JOHNSON-LEVONAS, Samuel S. ENGEL, Keith D. KAUFMAN, Barry J. GOLDSTEIN & Maria ALBA. (2012)
The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes*
†
. Journal of Diabetes 4:3, pages 227-237.
Crossref
Crossref
Mei Zhan, Ting Xu, Fengbo Wu & Yao Tang. (2012) Sitagliptin in the treatment of type 2 diabetes: a meta‐analysis. Journal of Evidence-Based Medicine 5:3, pages 154-165.
Crossref
Crossref
Seung-Chul Lee, Hyun Tae Kim, Choul-Hong Park, Do Young Lee, Ho-Jin Chang, Soobong Park, Joong Myung Cho, Sunggu Ro & Young-Ger Suh. (2012) Design, synthesis and biological evaluation of novel imidazopyridines as potential antidiabetic GSK3? inhibitors. Bioorganic & Medicinal Chemistry Letters 22:13, pages 4221-4224.
Crossref
Crossref
K. R. Gerrald, E. Van Scoyoc, R. C. Wines, T. Runge & D. E. Jonas. (2011) Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta‐analysis. Diabetes, Obesity and Metabolism 14:6, pages 481-492.
Crossref
Crossref
J. Wainstein, L. Katz, S. S. Engel, L. Xu, G. T. Golm, S. Hussain, E. A. O’Neill, K. D. Kaufman & B. J. Goldstein. (2011) Initial therapy with the fixed‐dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 14:5, pages 409-418.
Crossref
Crossref
A.J. Scheen. (2012) DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials. Diabetes & Metabolism 38:2, pages 89-101.
Crossref
Crossref
Jennifer A. HirstAndrew J. FarmerRaghib Ali, Nia W. RobertsRichard J. Stevens. (2012) Quantifying the Effect of Metformin Treatment and Dose on Glycemic Control. Diabetes Care 35:2, pages 446-454.
Crossref
Crossref
D. Williams‐Herman, L. Xu, R. Teng, G. T. Golm, J. Johnson, M. J. Davies, K. D. Kaufman & B. J. Goldstein. (2011)
Effect of initial combination therapy with sitagliptin and metformin on
β
‐cell function in patients with type 2 diabetes
. Diabetes, Obesity and Metabolism 14:1, pages 67-76.
Crossref
Crossref
Kathleen R. Richard, Jamie S. Shelburne & Julienne K. Kirk. (2011) Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review. Clinical Therapeutics 33:11, pages 1609-1629.
Crossref
Crossref
&NA;. (2011) Sitagliptin/metformin fixed-dose combination: a guide to its use in type 2 diabetes mellitus. Drugs & Therapy Perspectives 27:9, pages 1-5.
Crossref
Crossref
C. Reasner, L. Olansky, T. L. Seck, D. E. Williams-Herman, M. Chen, L. Terranella, A. O. Johnson-Levonas, K. D. Kaufman & B. J. Goldstein. (2011) The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 13:7, pages 644-652.
Crossref
Crossref
A. Pfützner, E. Paz-Pacheco, E. Allen, R. Frederich & R. Chen. (2011) Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes, Obesity and Metabolism 13:6, pages 567-576.
Crossref
Crossref
Antonio R Chacra, Gerry H Tan, Shoba Ravichandran, James List & Roland Chen. (2011) Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diabetes and Vascular Disease Research 8:2, pages 150-159.
Crossref
Crossref
Claudine M. Chwieduk. (2011) Sitagliptin/Metformin Fixed-Dose Combination. Drugs 71:3, pages 349-361.
Crossref
Crossref
K. H. Yoon, G. R. Shockey, R. Teng, G. T. Golm, P. R. Thakkar, A. G. Meehan, D. E. Williams-Herman, K. D. Kaufman, J. M. Amatruda & H. Steinberg. (2011) Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. International Journal of Clinical Practice 65:2, pages 154-164.
Crossref
Crossref
R. Arechavaleta, T. Seck, Y. Chen, K. J. Krobot, E. A. O’Neill, L. Duran, K. D. Kaufman, D. Williams-Herman & B. J. Goldstein. (2011) Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes, Obesity and Metabolism 13:2, pages 160-168.
Crossref
Crossref
Kathryn MS JohnsonKathleen Schurr. (2011) Sitagliptin: A DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus. Clinical Medicine Insights: Therapeutics 3, pages CMT.S6227.
Crossref
Crossref
Won Jun KimCheol-Young ParkEun Haeng JeongJeong Youn SeoJi Soo SeolSe Eun ParkEun Jung RheeWon Young LeeKi Won OhSung Woo ParkSun Woo Kim. (2011) Retrospective Analysis on the Efficacy, Safety and Treatment Failure Group of Sitagliptin for Mean 10-Month Duration. Diabetes & Metabolism Journal 35:3, pages 290.
Crossref
Crossref
Chidambarann SudhakaranUtkal KishoreRanjit Mohan AnjanaRanjit UnnikrishnanViswanathan Mohan. (2011) Effectiveness of Sitagliptin in Asian Indian Patients with Type 2 Diabetes—An Indian Tertiary Diabetes Care Center Experience. Diabetes Technology & Therapeutics 13:1, pages 27-32.
Crossref
Crossref
Jaime A. Davidson. (2010) Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors. Mayo Clinic Proceedings 85:12, pages S27-S37.
Crossref
Crossref
Debora Williams-Herman, Samuel S Engel, Elizabeth Round, Jeremy Johnson, Gregory T Golm, Hua Guo, Bret J Musser, Michael J Davies, Keith D Kaufman & Barry J Goldstein. (2010) Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocrine Disorders 10:1.
Crossref
Crossref
T. Forst, B. Uhlig-Laske, A. Ring, U. Graefe-Mody, C. Friedrich, K. Herbach, H.-J. Woerle & K. A. Dugi. (2010) Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. Diabetic Medicine 27:12, pages 1409-1419.
Crossref
Crossref
Elizabeth M. Migoya, Jutta L. Miller, Maria Gutierrez, Wei Zheng, Amy O. Johnson-Levonas, Qi Liu, Catherine Z. Matthews, John A. Wagner & Keith M. Gottesdiener. (2012) Bioequivalence of Sitagliptin/Metformin Fixed-Dose Combination Tablets and Concomitant Administration of Sitagliptin and Metformin in Healthy Adult Subjects. Clinical Drug Investigation 30:12, pages 855-866.
Crossref
Crossref
B. Cai, L. Katz, C. M. Alexander, D. Williams-Herman & C. J. Girman. (2010) Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database. International Journal of Clinical Practice 64:12, pages 1601-1608.
Crossref
Crossref
Milan K. Piya, Abd A. Tahrani & Anthony H. Barnett. (2010) Emerging treatment options for type 2 diabetes. British Journal of Clinical Pharmacology 70:5, pages 631-644.
Crossref
Crossref
R. Retnakaran, Y. Qi, C. Opsteen, E. Vivero & B. Zinman. (2010) Initial short‐term intensive insulin therapy as a strategy for evaluating the preservation of beta‐cell function with oral antidiabetic medications: a pilot study with sitagliptin. Diabetes, Obesity and Metabolism 12:10, pages 909-915.
Crossref
Crossref
D. Williams‐Herman, J. Johnson, R. Teng, G. Golm, K. D. Kaufman, B. J. Goldstein & J. M. Amatruda. (2010) Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 12:5, pages 442-451.
Crossref
Crossref
S. Skalli, N. Wion‐Barbot, M. Baudrant, S. Lablanche, P. Y. Benhamou & S. Halimi. (2010) Angio‐oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report. Diabetic Medicine 27:4, pages 486-487.
Crossref
Crossref
Sohita Dhillon. (2010) Sitagliptin. Drugs 70:4, pages 489-512.
Crossref
Crossref
P. Aschner, H. L. Katzeff, H. Guo, S. Sunga, D. Williams‐Herman, K. D. Kaufman & B. J. Goldstein. (2010) Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 12:3, pages 252-261.
Crossref
Crossref
Abd A. Tahrani, Milan K. Piya, Amy Kennedy & Anthony H. Barnett. (2010) Glycaemic control in type 2 diabetes: Targets and new therapies. Pharmacology & Therapeutics 125:2, pages 328-361.
Crossref
Crossref
Shelley R Salpeter, Elizabeth Greyber, Gary A Pasternak & Edwin E Salpeter (posthumous). 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
. (2009) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 18:9.
Crossref
Crossref
Thomas E Hughes. (2009) Emerging therapies for metabolic diseases—the focus is on diabetes and obesity. Current Opinion in Chemical Biology 13:3, pages 332-337.
Crossref
Crossref
Darleen A. Sandoval, Silvana Obici & Randy J. Seeley. (2009) Targeting the CNS to treat type 2 diabetes. Nature Reviews Drug Discovery 8:5, pages 386-398.
Crossref
Crossref